FDA Cracks Down on GLP-1 Compounding Pharmacies in US
• FDA announced new enforcement actions targeting compounding pharmacies producing GLP-1 drugs like semaglutide amid safety concerns. • The crackdown addresses risks from unapproved versions of weight-loss and diabetes medications flooding the market. • This policy shift aims to protect patients from potential contamination and dosing errors in the booming $100 billion GLP-1 sector.
ama-assn.org